Biomarker Candidates for Tumors Identified from Deep‐profiled Plasma Stem Predominantly from the Low Abundant Area

Case Studies

The case study elaborates on the results of our pan-cancer proteomics study. We analyzed 180 plasma samples from lung, breast, colorectal, pancreatic, and prostate cancer using our next-generation TrueDiscovery™ platform to discover actionable biomarkers.

Fill out the form to access this resource. Already a registered customer? Sign in to access this resource.

First Name

Last Name

Phone

Company

Job Title

Country

Select state:

By selecting any or all of the topic preferences below, you agree to receive respective information from Biognosys via email. You can unsubscribe from these communications at any time. Contract Research Services Products (Software, Kits, Reagents) Science & Technology By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

Back to Resources overview

Contact

Contact Form

Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland

Phone: +41 44 738 20 40

US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States

in

By Platforms & Applications

By Therapeutic Areas

By Research Phases

HIDDEN

Software

Kits

in

Biomarker Candidates for Tumors Identified from Deep‐profiled Plasma Stem Predominantly from the Low Abundant Area

Case Studies

Contact

New: Spectronaut^® 19

New: Spectronaut^® 19

Quick find

Follow us

By Platforms & Applications

By Therapeutic Areas

By Research Phases

HIDDEN

Software

Kits

in

Biomarker Candidates for Tumors Identified from Deep‐profiled Plasma Stem Predominantly from the Low Abundant Area

Case Studies

Fill out the form to access this resource. Already a registered customer? Sign in to access this resource.

Contact

New: Spectronaut® 19

New: Spectronaut® 19

Quick find

Follow us

Newsletter

New: Spectronaut^® 19

New: Spectronaut^® 19